Abstract
Gemcitabine (2'-2'-difluorodeoxycytidine) is a well-known cytotoxic drug and a potent radio-enhancer. We herein report the in vitro evidence of its activity, and the clinical experiences when this drug is administered concurrently with radiation. The phase I-II trials are analyzed, focusing on the recent ability to deliver irradiation with low incidence of side effects.
Lingua originale | Inglese |
---|---|
pagine (da-a) | 52-54 |
Numero di pagine | 3 |
Rivista | Annals of Oncology |
Volume | 17 |
DOI | |
Stato di pubblicazione | Pubblicato - 2006 |
Keywords
- lung cancer